SpliSense Company

Splisense develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Technology: Biotechnology, Life Science, Pharmaceutical
Industry: Personalized Medicine
Headquarters: Jerusalem, Israel
Founded Date: 2016
Employees Number: Undisclosed
Funding Status: Seed

Visit Website
liana@integra-holdings.com
Register and Claim Ownership